Stock Taper
Molecular Partners AG is a Swiss clinical-stage biopharmaceutical company developing DARPin-based therapeutics for ophthalmology, oncology, and infectious diseases, with collaborations including Novartis, Amgen, and AbbVie.

An investigational multi-specific DARPin therapy targeting three tumor antigens, currently in Phase 1 trials for AML and MDS, is Molecular Partners' most advanced candidate, aiming to activate the immune system against cancer cells.
| Map | REGION | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
![]() | SWITZERLAND | — | $179.9M | $7.04M ▼ | $4.97M ▼ |
![]() | UNITED STATES | $9.33M | $9.65M ▲ | $0 ▼ | — |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
ALEC | $2.34 | COMPARE |
PEPG | $3.08 | COMPARE |
CRBP | $10.91 | COMPARE |
NKTX | $2.76 | COMPARE |
MIST | $1.16 | COMPARE |
CRDF | $0.94 | COMPARE |
RANI | $0.84 | COMPARE |
ELTX | $2.84 | COMPARE |